NEW YORK (GenomeWeb News) – Rosetta Genomics said this week that Brian Markison has become an observer to the company's board of directors and that he will become a director at the firm upon approval. Markison currently is chairman and CEO of King Pharmaceuticals, where he led the company through to its recently announced acquisition by Pfizer, and before that he was at Bristol-Myers Squibb, where he served as president of BMS Oncology/Virology and Oncology Therapeutics Network.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.